search icon
  • Print
  • ShareThis
  • Text Size


In order to add a post to the discussion forum you need to be an IDSA member. If you are an IDSA member, please login now. Please read our Discussion Forum Guidelines and Terms of Use before joining.

Hepatitis C

Welcome to Hepatitis C Management Discussion Board! The Hepatitis C Management Discussion Board provides Infectious Disease Clinicians a platform to connect with colleagues to exchange information, case studies, complications, and new developments on matters concerning hepatitis C treatment and management. Certain case studies will be developed into clinical vignettes and will be available to Infectious Disease Clinicians for future reference. Please be respectful of all participants and their respective comments. Please read our Terms of Use and Discussion Forum Guidelines.

 

Any diagnostic or therapeutic recommendations and all opinions presented are those of the individual contributor. They do not necessarily represent the views of IDSA. The reader assumes all risks in using this information. The IDSA Hepatitis C Discussion Forum is in full compliance with HIPPA. IDSA bears no responsibility for the accuracy of participant comments and will bear no legal liability for discussion results.

If a participant wishes to post an issue on the IDSA Hepatitis C Discussion Forum, the participant is strongly urged to provide contact information for possible offline discussion via phone or email concerning the posted issue.


RSS Feed Print Category View
FDA approves Sovaldi for chronic hepatitis C
ThomasKim
Posted: Monday, December 9, 2013 9:08 AM
Joined: 2/20/2013
Posts: 38


"The U.S. Food and Drug Administration today approved Sovaldi (sofosbuvir) to treat chronic hepatitis C virus (HCV) infection. Sovaldi is the first drug that has demonstrated safety and efficacy to treat certain types of HCV infection without the need for co-administration of interferon.

 
'Today’s approval represents a significant shift in the treatment paradigm for some patients with chronic hepatitis C,' said Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research.

 

Sovaldi is the second drug approved by the FDA in the past two weeks to treat chronic HCV infection. On November 22, the FDA approved Olysio (simeprevir)."

 

To read more, please visit: 

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm377888.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

Also, please see the attached New York Times article, "F.D.A. Approves Pill to Treat Hepatitis C."


File Attachment(s):
FDA approves Sovaldi - Gilead Science - Dec 6 2013 - NYTimes.doc (45056 bytes)

 

| HIVMA | Contact Us

© Copyright IDSA 2014 Infectious Diseases Society of America

Full Site Mobile Site